GENE MUTATED

LUNG CANCER CAUSED BY THIS MUTATION

BEST THERAPY

p53 genes

Half of lung cancer cases (microcellular lung cancer (70%) and adenoid lung cancer (33%)

Auranofin

EGFR mutation

10-15% of lung cancer generally appears in adenocarcinoma

Osimertinib and if resistance is developed use dabrafenib and trametinib

KRAS mutation

adenocarcinoma

trametinib/FGFR inhibitor

ALK mutation

5% percent of patients have NSCLC commonly adenocarcinoma

Lorlatinib (best results)

Alectinib (safest profile)

BRAF mutation

4% of NSCLC usually adenocarcinoma

Trametinib in combination with dabrafenib (BRAF inhibitor)

ROS1 oncogenic fusion

1%–2% of NSCLC and 4% of lung adenocarcinoma

Crizotinib

HER2 mutation

1–2% of lung adenocarcinomas

trastuzumab deruxtecan

Rearranged during transfection (RET) mutation

1%–2% of NSCLC patients are usually associated with female young Asian non-smokers patients

Pralsetinib and Selpercatinib

MET mutation

adenocarcinoma and squamous NSCLC and about 5% of lung cancer

Capmatinib

AKT1 mutation

0.69% of all squamous cell lung carcinoma

pan-AKT inhibitor AZD5363

FGFR1 amplification

20% of squamous cell cancers

combination therapy of FGFR/PLK1 inhibitors